Ventilator Associated Bacterial Pneumonia (VABP)NCT07854730
Effect of Ventilator Hyperinflation Combined With Body Positioning on ABG in VAP
A study testing Ventilator hyperinflation and Manual hyperinflation in people with Ventilator Associated Bacterial Pneumonia (VABP) and Critical Illness, run by Al-Zaytoonah University of Jordan at 1 site in Egypt.
Trial summary
This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral… Read more about this study
- Who is it for?
- Ages 40 to 60 years
- Conditions the study is for
- Ventilator Associated Bacterial Pneumonia (VABP), Critical Illness
- What is being tested?
- Ventilator hyperinflation and Manual hyperinflation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 5 Oct 2026to 15 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Mechanically ventilated patients ≥ 48 hours
- Diagnosed with VAP (clinical + chest X-ray)
- Age: 40-60 years
- Hemodynamically stable
- Unilateral lung involvement
Who cannot join
- Bilateral lung disease
- Unstable cardiovascular conditions
- Contraindications to positioning
- Re-intubation cases
- Presence of pneumothorax or air leak
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Mohamed Saied Zidan
Cairo, 11571
Mohamed S Zidan, phd, 01016469801, drmohzidan2015@gmail.com
Mohamed S Zidan, 01016469801
About this study
Official title: Effect of Ventilator Hyperinflation Combined With Body Positioning on Arterial Blood Gases In Patients With Ventilator-Associated Pneumonia : A Randomized Controlled Trial
This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral decubitus positions. Arterial blood gases will be assessed over a 6-day intervention period. The findings are expected to provide evidence regarding the optimal positioning strategy to enhance the effectiveness of ventilator hyperinflation in improving gas exchange in critically ill patients.
- Being tested
- Ventilator hyperinflation, Manual hyperinflation
- Medical subject headings
- Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ventilator hyperinflationDevice
a therapeutic technique used by clinicians (Manual or Ventilator Hyperinflation) to clear secretions and recruit collapsed lung tissue, or an inadvertent complic
Manual hyperinflationDevice
a respiratory therapy technique that uses a manual resuscitation bag to deliver larger-than-normal, controlled breaths to clear airway secretions and reopen collapsed lung areas
| Study group | Role | What they receive |
|---|---|---|
| ventilator hyperinflation from lateral decubitus position | Experimental | This group will receive Ventilator hyperinflation in lateral decubitus position (affected lung uppermost) and Conventional respiratory physiotherapy Receives: Device: Ventilator hyperinflation |
| Manual hyperinflation for Lateral decubitus position | Experimental | This group will receive manual hyperinflation in Lateral decubitus position and Conventional respiratory physiotherapy Receives: Device: Manual hyperinflation |
What is being measured
The primary outcome is the main question the study is designed to answer.
PaCO2
partial pressure of carbon dioxide in arterial blood, measuring how effectively the lungs eliminate carbon dioxide
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
PaO2
partial pressure of oxygen dissolved in arterial blood plasma, measured through an Arterial Blood Gas (ABG) test.
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
SaO2
the percentage of oxygen-saturated hemoglobin relative to total hemoglobin in arterial blood, typically measured via an invasive arterial blood gas (ABG) analysis with normal values ranging from 95% to 99%
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
PaO2/FiO2 (P/F)
a clinical metric used to evaluate oxygenation efficiency and diagnose the severity of acute hypoxemic respiratory failure or Acute Respiratory Distress Syndrome (ARDS).
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
Secondary outcomes (1)
Pulmonary compliance
the change in lung volume divided by the change in pressure (Δ V / Δ P). Higher compliance means the lungs stretch easily; lower compliance means they are stiff and harder to inflate
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study start5 Oct 2026
- Primary completion15 Nov 2026 (estimated)
- Study completion15 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ventilator Associated Bacterial Pneumonia (VABP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Al-Zaytoonah University of Jordan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Saied Zidan, Al-Zaytoonah University of Jordan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07854730
- Sponsor's protocol ID
- IRB # 14/5/2025-2026
- Status last verified
- Oct 2026
- First submitted
- 27 Sep 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Ventilator Hyperinflation Combined With Body Positioning on Arterial Blood Gases In Patients With Ventilator-Associated Pneumonia : A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07854730
- Acronym / sponsor ID
- IRB # 14/5/2025-2026
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Al-Zaytoonah University of JordanUniversity, hospital or other
- Study start
- 5 Oct 2026 (actual)
- Primary completion
- 15 Nov 2026 (estimated)
- Study completion
- 15 Nov 2026 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral decubitus positions. Arterial blood gases will be assessed over a 6-day intervention period. The findings are expected to provide evidence regarding the optimal positioning strategy to enhance the effectiveness of ventilator hyperinflation in improving gas exchange in critically ill patients.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ventilator hyperinflation from lateral decubitus position | Experimental | Device: Ventilator hyperinflationThis group will receive Ventilator hyperinflation in lateral decubitus position (affected lung uppermost) and Conventional respiratory physiotherapy |
| Manual hyperinflation for Lateral decubitus position | Experimental | Device: Manual hyperinflationThis group will receive manual hyperinflation in Lateral decubitus position and Conventional respiratory physiotherapy |
Who may qualify
- Ages
- 40 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Mechanically ventilated patients ≥ 48 hours
- Diagnosed with VAP (clinical + chest X-ray)
- Age: 40-60 years
- Hemodynamically stable
- Unilateral lung involvement
Key exclusion criteria (5 listed)
- Bilateral lung disease
- Unstable cardiovascular conditions
- Contraindications to positioning
- Re-intubation cases
- Presence of pneumothorax or air leak
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ventilator hyperinflationa therapeutic technique used by clinicians (Manual or Ventilator Hyperinflation) to clear secretions and recruit collapsed lung tissue, or an inadvertent complic | Device | ventilator hyperinflation from lateral decubitus position |
| Manual hyperinflationa respiratory therapy technique that uses a manual resuscitation bag to deliver larger-than-normal, controlled breaths to clear airway secretions and reopen collapsed lung areas | Device | Manual hyperinflation for Lateral decubitus position |
Primary outcome
PaCO2
Time frame: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
partial pressure of carbon dioxide in arterial blood, measuring how effectively the lungs eliminate carbon dioxide
PaO2
Time frame: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
partial pressure of oxygen dissolved in arterial blood plasma, measured through an Arterial Blood Gas (ABG) test.
SaO2
Time frame: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
the percentage of oxygen-saturated hemoglobin relative to total hemoglobin in arterial blood, typically measured via an invasive arterial blood gas (ABG) analysis with normal values ranging from 95% to 99%
PaO2/FiO2 (P/F)
Time frame: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
a clinical metric used to evaluate oxygenation efficiency and diagnose the severity of acute hypoxemic respiratory failure or Acute Respiratory Distress Syndrome (ARDS).
1 secondary outcome
Pulmonary compliance
Time frame: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
Related trials for Ventilator Associated Bacterial Pneumonia (VABP)
Not yet recruitingPhase 3
Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
RecruitingPhase 2
ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Ventilator-associated Bacterial Pneumonia (VABP), Hospital-acquired Bacterial Pneumonia (HABP)
Not yet recruitingPhase 3
A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
RecruitingPhase 3
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
Not yet recruitingPhase 2
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ventilator hyperinflation and Manual hyperinflation in people with Ventilator Associated Bacterial Pneumonia (VABP) and Critical Illness, run by Al-Zaytoonah University of Jordan at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PaCO2 (time frame: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026; AzTrials last refreshed its copy on 6 Nov 2026.